Welcome to Markets Desk, your midday read on the stories moving money and markets.
SoftBank's Masayoshi Son is making a bold call, telling CNBC that the artificial intelligence revolution will be fifty times larger than the dotcom boom of the early two thousands. That is a staggering multiplier from a man who has both won and lost enormous bets on technology cycles, and it signals that institutional capital is nowhere near done pouring into the AI trade.
Shifting to pharmaceuticals, Eli Lilly is drawing comparisons to Nvidia's historic run, and those comparisons are not entirely without merit. The company recently secured approval for a new addition to its weight loss portfolio, deepening its dominance in the GLP-one space and giving bulls a fresh catalyst to argue the stock has more runway than the market is currently pricing in.
And in deal-making, restaurateur and Houston Rockets owner Tilman Fertitta is making an eighteen billion dollar move on Caesars Entertainment, a bet that combines hospitality scale with gaming exposure. He's targeting fifty new locations despite real headwinds — rising operating costs, the Ozempic effect on consumer behavior, and a significant debt load that will demand careful execution.
That's the tape. Markets Desk, signing off the floor.
